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The hereditary transthyretin (TTR) amyloidoses are a group of diseases for which several
disease-modifying treatments are now available. Long-term effectiveness of these therapies
is not yet fully known. Moreover, the existence of alternative therapies has resulted in an
urgent need to identify patient characteristics that predict response to each therapy.
We carried out a retrospective cohort study of 210 patients with hereditary TTR amyloidosis
treated with the kinetic stabilizer tafamidis (20 mg qd). These patients were followed for a
period of 18–66 months, after which they were classified by an expert as responders, partial
responders, or nonresponders. Correlations between baseline demographic and clinical
characteristics, as well as plasma biomarkers and response to therapy, were investigated.
34% of patients exhibited an almost complete arrest of disease progression (classified by an
expert as responders); 36% had a partial to complete arrest in progression of some but not
all disease components (partial responders); whereas the remaining 30% continued
progressing despite therapy (nonresponders). We determined that disease severity, sex,
and native TTR concentration at the outset of treatment were the most relevant predictors of
response to tafamidis. Plasma tafamidis concentration after 12 months […]
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Introduction
Hereditary or familial transthyretin (TTR) amyloidoses (hATTRs) are a group of  autosomal dominant 
degenerative diseases associated with one of  the established 124 amyloidogenic mutations in the TTR 
gene (1, 2). The most common TTR mutation involves substitution for valine at position 30 by methionine 
(TTRVal30Met) (3), which is linked with familial amyloid polyneuropathy (FAP), a form of  hATTR that 
presents with a predominantly neurological phenotype characterized by a progressive sensory, motor, and 
autonomic axonal neuropathy, with variable involvement of  other organs (4, 5). If  untreated, this disease 
is physically incapacitating in ≤5 years and invariably fatal in less than 2 decades (6, 7). This motivated 
the development of  a fit-for-purpose small molecule kinetic stabilizer (tafamidis) (8) and one nonsteroidal 
antiinflammatory drug repurposed as a TTR kinetic stabilizer (diflunisal) (9), followed more recently by 
two approved oligonucleotide-based TTR mRNA–lowering drugs (10, 11). The availability of  distinct ther-
apeutic strategies for FAP raises the question of  which drug to prioritize. Outcome predictors to specific 
therapies — i.e., baseline (or before treatment) demographic and clinical characteristics, as well as plasma 
biomarkers that help to determine which patients are more likely to respond to a certain drug — are essen-
tial in the emerging era of  personalized precision medicine.
BACKGROUND. The hereditary transthyretin (TTR) amyloidoses are a group of diseases for which 
several disease-modifying treatments are now available. Long-term effectiveness of these 
therapies is not yet fully known. Moreover, the existence of alternative therapies has resulted in an 
urgent need to identify patient characteristics that predict response to each therapy.
METHODS. We carried out a retrospective cohort study of 210 patients with hereditary TTR 
amyloidosis treated with the kinetic stabilizer tafamidis (20 mg qd). These patients were followed 
for a period of 18–66 months, after which they were classified by an expert as responders, 
partial responders, or nonresponders. Correlations between baseline demographic and clinical 
characteristics, as well as plasma biomarkers and response to therapy, were investigated.
RESULTS. 34% of patients exhibited an almost complete arrest of disease progression (classified 
by an expert as responders); 36% had a partial to complete arrest in progression of some but not 
all disease components (partial responders); whereas the remaining 30% continued progressing 
despite therapy (nonresponders). We determined that disease severity, sex, and native TTR 
concentration at the outset of treatment were the most relevant predictors of response to 
tafamidis. Plasma tafamidis concentration after 12 months of therapy was also a predictor of 
response for male patients. Using these variables, we built a model to predict responsiveness to 
tafamidis.
CONCLUSION. Our study indicates long-term effectiveness for tafamidis, a kinetic stabilizer 
approved for the treatment of hereditary TTR amyloidosis. Moreover, we created a predictive 
model that can be potentially used in the clinical setting to inform patients and clinicians in their 
therapeutic decisions.
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Tafamidis kinetically stabilizes the TTR tetramer, slowing its dissociation into monomers, which after mis-
folding enables aggregation that appears to be responsible for postmitotic cell dysfunction and death (12). Several 
observational open-label studies have been published after the registration trial showing that use of tafamidis 
halts or slows the progression of FAP, whereas others suggest that tafamidis is less effective in later-stage patients 
(7, 13–17). The North of Portugal has the highest number of patients worldwide exhibiting TTRVal30Met FAP 
(18). The FAP Reference Center in Porto (Unidade Corino de Andrade [UCA]) has ~300 patients treated with 
tafamidis (20 mg qd). Moreover, since the disease was first described in 1952 in Porto, UCA has followed more 
than 800 families with this mutation, including the longitudinal follow-up of presymptomatic mutation carriers.
Herein, we report a longitudinal follow-up study of  210 FAP patients treated with tafamidis (20 mg 
qd) for a maximum period of  66 months, with 2 main aims. First, we intended to scrutinize the long-term 
effectiveness of  tafamidis in a large group of  patients. Second, we sought baseline demographic and clinical 
characteristics, as well as plasma biomarkers that can be used as tafamidis outcome predictors. These fac-
tors were used to build a predictive model that is also described here.
Results
Study population. From July 2012 to January 2016, 306 patients were considered eligible to start tafamidis 
therapy at UCA (Figure 1A). Of  those, 96 were excluded from this cohort study based on preestablished 
exclusion criteria (Supplemental Table 1; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.126526DS1). All patients had at least 18 months of  follow-up, and about half  
were followed for at least 48 months (Supplemental Figure 1).
Genetic, demographic, and clinical baseline characteristics for all patients included in this study are 
shown in Table 1. The majority of  patients were heterozygous for the common TTRVal30Met mutation. The 
median age at disease onset was 34 years, reflecting a higher proportion of  early-onset cases, as described for 
the Portuguese FAP patient population (18). Median disease duration at baseline was 2 years, also reflecting 
the situation within a clinical center that follows a large number of  asymptomatic mutation carriers.
All patients presented with a predominantly neuropathic phenotype, characterized by length-depen-
dent axonal sensory-motor and autonomic neuropathy. No asymptomatic mutation carriers were included 
in this study, as they are not eligible for therapy with tafamidis according to the current country guidelines. 
Outcome measures developed and validated for other neuropathies have been adapted and used in several 
clinical trials for FAP, including the neuropathy impairment score (NIS, an outcome measure based on 
objective evaluation of  lower- and upper-limb sensory-motor function and reflexes by a trained neurologist; 
refs. 8, 19, 20); and the Norfolk Quality of  Life Questionnaire–Diabetic Neuropathy (Norfolk QOL-DN 
[ref. 21]; a patient-reported outcome measure, sensitive to different features of  this neuropathy, including 
autonomic involvement). More severely affected patients have higher NIS and/or Norfolk QOL-DN val-
ues. Additionally, we characterized sensory and motor neurological involvement by measuring sensory 
nerve action potentials (SNAPs) and compound motor action potentials (CMAPs) on routine nerve con-
duction tests. Our resulting neurophysiological score (SNF) is defined as follows:
SNF = SNAPulnar nerve + SNAPsural nerve + CMAPulnar nerve + CMAPtibial nerve + CMAPperoneal nerve
(Equation 1)
More severely affected patients have low SNAPs and/or CMAPs, resulting in a lower SNF. As expected 
based on the short median disease duration, most patients included in this study had mild to moderate 
disease, represented by a median baseline NIS of  8 points (Table 1).
Response classification. As expected in a complex disease such as FAP, no single available outcome mea-
sure reflects disease progression fully (20). For example, symptoms such as severe diarrhea, urinary retention, 
and erectile dysfunction, resulting from autonomic nervous system involvement, are frequently seen in these 
patients (4, 22). Changes in these disease manifestations are not captured by NIS or SNF. Additionally, the 
impact of these symptoms in each patient’s quality of life can be highly variable. For this reason, we based our 
response classification on an expert opinion. At the end of the observation period, a clinical expert in TTR-
FAP on our research team individually reviewed each patient record, including neurology, cardiology and 
nephrology visits, as well as NIS, neurophysiology data, quality-of-life evaluations, and weight measurements. 
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Based on this complete evaluation, patients were classified as responders, partial responders, and nonrespond-
ers (Figure 1A). Seventy-two patients (34%) were considered to have no discernible disease progression and 
were therefore classified as responders. Change in NIS, calculated as the difference between NIS at each time 
point and NIS at baseline, showed that responders’ disease was mostly stable or improved (i.e., NIS change 
from baseline ≤0 for almost the entire study period; Figure 1B, green line). Continuous worsening of sensory, 
motor, and/or autonomic neuropathy, not different from the expected progression without therapy, was seen in 
62 patients (30%), who were classified as nonresponders. This group showed an NIS increase from baseline of  
3 points or more, after 18 months of treatment with tafamidis (Figure 1B, red line). An additional group of 76 
patients (36%) were classified as partial responders, including patients whose autonomic nervous system mani-
festations improved dramatically while their sensory and/or motor neuropathy still progressed, or patients who 
continued progressing overall, albeit more slowly than nonresponders. Accordingly, this group showed an NIS 
increase from baseline of 1 point or more, also after 18 months of treatment with tafamidis (Figure 1B, blue 
line). Overall, when the rate of NIS change was analyzed, responders remained stable (0 points/yr), while par-
tial responders increased 1.8 points/yr, and nonresponders increased 5.9 points/yr (Supplemental Figure 2). 
As explained above, the overlap of the rates of change in NIS seen among the 3 groups reflects the existence of  
other disease manifestations that are not measured by NIS, but which were considered in our expert classifica-
tion. For example, responders and partial responders can be separated from nonresponders, as the first 2 groups 
gained weight or remained stable significantly more than nonresponders for the first 4 years of follow-up (Fig-
ure 1C). The same results were observed with modified BMI (Supplemental Figure 3).
Figure 1. Patients can be classified in 3 groups according to expert opinion and selected outcome measures. (A) Study flowchart. (B) NIS change from baseline 
and (C) change in weight (in kg) from baseline according to expert opinion response classification in 3 groups. x axis in B and C represent number of follow-up 
months (m); numbers below B and C represent number of patients evaluated at each time point (NR, nonresponders; PR, partial responders; R, responders). 
Data are shown as median, with error bars representing interquartile range; P values were calculated using Kruskal-Wallis test with Dunn’s multiple-comparisons 
correction. *P < 0.05, **P < 0.01; P values are only shown when differences exist between the 3 groups using multiple-comparisons correction.
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Norfolk QOL-DN data were collected at baseline and yearly after the start of  tafamidis treatment. 
Interestingly, no differences in changes to the Norfolk QOL-DN data existed among patients who were 
classified as responders, partial responders, and nonresponders (Supplemental Figure 4).
In summary, our data suggest that in the long-term commercial setting, tafamidis fully stabilizes neu-
ropathy and weight loss in about one-third of  FAP patients. Additionally, another third exhibited slower 
overall disease progression, or continued progressing, while having clear improvements from autonomic 
neuropathy and weight loss. Finally, these data also suggest that despite therapy with tafamidis, about a 
third of  patients continue progressing as rapidly as untreated FAP patients.
Clinical and demographic baseline outcome predictors. We next sought to investigate baseline characteris-
tics that could help predict response to tafamidis. In a univariate analysis, sex was a strong predictor of  
response, with women more likely to become responders than men (Table 2).
Disease severity was the next sex-independent predictor variable. Patients with mild neurological 
impairment at baseline, as reflected by a median NIS of  6 and SNF of  70.5, were significantly more likely to 
become responders. In addition, moderate disease at baseline was significantly linked with partial response, 
while more advanced patients were less likely to respond well to tafamidis (Table 2). Baseline patient quali-
ty-of-life self-assessment measured by Norfolk QOL-DN was also able to distinguish responders from non-
responders, with patients reporting worse quality of  life more likely to become nonresponders (Table 2).
Age at baseline, age at disease onset, and disease duration were not predictors of  response to tafamidis 
(Supplemental Table 2). Routine laboratory tests — including renal, liver, and thyroid function, lipid pro-
file, complete blood count, general inflammatory markers, uric acid, and iron — did not show significant 
differences among the 3 groups at baseline (Supplemental Table 2).
Baseline plasma biomarkers predicting outcome. Plasma TTR levels were previously reported to be lower in 
patients with TTR amyloidoses (23). Moreover, low TTR levels have been associated with a decrease in survival 
in patients with WT-TTR cardiomyopathy (24). In order to determine whether there were significant differences 
among the 3 groups in tetrameric TTR levels at baseline, we measured TTR concentration (CTTR) employing a 
fluorogenic small molecule (A2) that binds and reacts with natively folded TTR, rendering the conjugate fluores-
cent, which when combined with ultra-performance liquid chromatography (UPLC) separation enables quan-
tification of native TTR tetramer (25, 26). We found that patients who become responders had higher levels of  
tetrameric TTR (3.0 μM) than partial responders (2.7 μM) and nonresponders (2.3 μM) at baseline (Table 2 and 
Figure 2A). This difference was not explained by sex differences in plasma TTR levels (Figure 2B). Likewise, 
CTTR showed weak or no correlation with disease severity, as measured by SNF (Figure 2C) and NIS (Figure 2D). 
This suggests that tetrameric TTR levels can be used as an independent predictor of response to therapy, i.e., 
patients who have higher levels of tetrameric TTR are more likely to become responders.
Troponin T, a measure of  cardiac muscle damage, was significantly lower at baseline in the responders 
compared with the other 2 groups (Table 2). This difference was independent of  sex (P = 0.136, Mann-Whit-
Table 1. Genetic, demographic, and clinical characteristics of the study population at baseline
Study population (n = 210)
Genotype Val30Met/WT: 206 (98.1%), Val30Met/Val30Met: 2 (1.0%), 
Val28Met/WT: 1 (0.5%), Val30Met/Thr119Met: 1 (0.5%)
Sex F:M (%M) 93:117 (55.7%)
Age of disease onset (yr) 34.1 (29.0–43.1; 19.6–81.0)
Age at baseline (yr) 36.5 (32.0–45.7; 22.5–84.3)
Disease duration at baseline (yr) 2.1 (1.3–3.6; 0.3–16.5)
NIS 8 (4–16; 0–116)
Norfolk QOL-DN (n = 201) 22 (10–38; 0–108)
SNF (n = 207) 57.9 (32.8–79.0; 0.1–139.7)
F, female; M, male. Median values are shown for all continuous variables; interval between the first quartile (Q1) and 
the third quartile (Q3) is shown in parentheses; minimum and maximum are also included between parenthesis in 
italic. Nine patients did not complete the Norfolk QOL-DN questionnaire at baseline and 3 patients did not perform 
baseline neurophysiological measurements. NIS, neuropathy impairment score; Norfolk QOL-DN, Norfolk Quality of Life 
Questionnaire–Diabetic Neuropathy; SNF, neurophysiological score.
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ney U test); however, there was a correlation between troponin T values and disease severity as measured 
by SNF (Spearman’s correlation coefficient = –0.59, P < 0.0001) and NIS (Spearman’s correlation coefficient 
= 0.49, P = 0.0003). Although the number of  patients for whom troponin T values were available was low 
(n = 51), this suggests that having less cardiac involvement might be also predictive of  a better response to 
tafamidis, albeit not independent from the other measures of  clinical severity.
Tafamidis and extent of  TTR stabilization in plasma correlates with clinical outcome. Next, we hypothesized 
that the tafamidis plasma concentration, which correlates with the extent of  TTR kinetic stabilization, could 
explain why some patients respond to tafamidis better than others (26). TTR tetramer dissociation into mono-
mers is the rate-limiting step of  the TTR amyloidogenesis cascade. The process of  TTR amyloidogenesis is 
thought to be the cause of  tissue degeneration and disease progression (27). Tafamidis acts by kinetically 
stabilizing the TTR tetramer, slowing down tetramer dissociation into monomers, and consequently slowing 
aggregation and disease progression (12) (Figure 3A). We developed biochemical methods to measure total 
tafamidis plasma concentration (CTaf) (26), as well as a TTR subunit exchange method to quantify the rate of  
tetramer dissociation to monomers in plasma (25). When analyzing CTaf by response classification, we found 
that nonresponders had significantly lower tafamidis levels (Figure 3B; 6.8 μM) than partial responders (8.4 
μM) and responders (8.7 μM). The same difference was seen at 24 months of  therapy, and the same tendency 
was found in the samples for which a last time point (more than 24 months) was analyzed (Supplemental 
Figure 5, A and B). These patients were all taking tafamidis meglumine 20 mg once daily (corresponding 
to 12.5 mg tafamidis). Blood samples were collected at the time of  the visit, and information regarding the 
last tafamidis dose was not collected. However, tafamidis levels at 12 months correlated well with tafamidis 
levels at 24 months within the same individual, and the overall differences between 12 and 24 months were 
not significant, suggesting that temporal variations in drug levels were minor (Supplemental Figure 6, A and 
B). This was not unexpected based on the reported long half-life of  tafamidis (~50 hours). Interestingly, when 
analyzing men and women separately, we found that the differences in CTaf between different response groups 
were driven entirely by male patients (Figure 3C, CTaf NR-women = 8.4 μM, CTaf PR-women = 9.2 μM, CTaf R-women = 8.4 
μM; and Figure 3D, CTaf NR-men = 6.3 μM, CTaf PR-men = 7.6 μM, CTaf R-men = 9.7 μM).
CTaf should correlate with the extent of  TTR tetramer kinetic stabilization (defined as the difference 
between the rate of  tetramer dissociation at 12 months or 24 months and the rate of  tetramer dissociation 
at baseline), and it did (Figure 3E and Supplemental Figure 7A), reflecting target engagement. Consis-
tent with the differences in CTaf reported above, the extent of  stabilization was also different according to 
response classification in male patients (Figure 3F).
According to these observations, CTaf, and consequently, the extent of  TTR tetramer stabilization, is a 
predictor of  response only in male patients. This suggests that additional mechanisms for nonresponse may 
play an important role in women.
Factors that influence CTaf. Interestingly, our data show that CTaf has a wide range of  concentrations, i.e., 
from ~20 μM to ~0 μM (Figure 3B). We next sought to investigate factors that could help explain this 
Table 2. Baseline characteristics by response classification group
Responders (R) Partial responders (PR) Nonresponders (NR) R vs. NR R vs. PR PR vs. NR
Demographic characteristics
Sex (%F) 68.1% 35.5% 27.4% <0.0001 <0.0001 NS
Disease severity
NIS 6 (4–10) 10 (6–5) 14 (8–31) <0.0001 0.004 0.014
SNF 70.5 (56.2–96.1) 58.0 (35.7–77.3) 30.5 (16.5–55.5) <0.0001 0.0002 0.003
Norfolk QOL-DN 16 (9–29) 20.5 (11–36) 28.5 (14–52) 0.002 NS NS
Plasma biomarkers
Troponin T (ng/mL) 0.007 (0.004–0.011) 0.013 (0.007–0.019) 0.013 (0.010–0.028) 0.015 0.033 NS
CTTR (μM) 3.0 (2.3–3.8) 2.7 (2.1–3.3) 2.3 (1.5–3.1) 0.002 NS NS
Median values are shown for all continuous variables; interval between Q1 and Q3 is shown in parentheses. P values for continuous variables were 
calculated using a Kruskal-Wallis test with Dunn’s multiple-comparisons correction; P values for sex were calculated using a χ2 test. Troponin T values were 
only available from 51 patients (21 responders, 18 partial responders, 12 nonresponders); CTTR is the concentration of TTR in plasma, also shown in Figure 
2A. NIS, neuropathy impairment score; SNF, neurophysiological score; Norfolk QOL-DN, Norfolk Quality of Life Questionnaire–Diabetic Neuropathy.
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variation in CTaf. In general, drug levels are influenced by sex, age, drug absorption and metabolism, body 
weight and size, and renal and/or hepatic impairment (28). Women had overall higher levels of  tafamidis 
in plasma at 12 months than men (8.6 μM versus 7.6 μM, Figure 4A), but this difference was not statistical-
ly significant. Moreover, at 24 months, both men and women had the same median CTaf in plasma (7.6 μM; 
Figure 4B). When adjusting for BMI, there were no significant differences in CTaf between men and women 
at 12 months (CTaf men = 0.34 μM/[kg/m
2], CTaf women = 0.35 μM/[kg/m
2]) and 24 months (CTaf men = 0.36 μM/
[kg/m2], CTaf women = 0.33 μM/[kg/m
2]).
Differences in metabolism could also explain some of  the CTaf variation. Approximately 20% of  taf-
amidis is reported to be metabolized by glucuronidation to acylglucuronide (herein referred to as tafa-
midis-gluc.). If, in fact, patients with low CTaf are faster metabolizers, one would expect to find higher 
tafamidis-gluc. levels in the plasma of  patients with low unmetabolized tafamidis. We were able to detect 
the peak corresponding to tafamidis-gluc. in plasma of  patients taking tafamidis by comparison to synthe-
sized tafamidis-gluc. (Supplemental Figure 8, A–D). By comparing the area of  the metabolite peak (elution 
volume 9 mL) with the area of  the unmetabolized drug (elution volume 13 mL), we found a strong positive 
correlation between the two, suggesting that increased glucuronidation is unlikely to explain low tafamidis 
levels (Figure 4C). In the subset of  patients analyzed, tafamidis-gluc. represented 1%–15% of  the total CTaf.
Finally, we did not find significant correlation between tafamidis plasma levels and age, weight, BMI 
and modified BMI (mBMI), estimated glomerular filtration rate (eGFR; measure of  renal function) and 
asparate aminotransferase (AST; measure of  hepatic function) at 12 or 24 months (Table 3). Only alanine 
aminotransferase (ALT; measure of  hepatic function) at 24 months had a weak correlation with tafamidis 
levels (r < −0.20, Table 3).
In summary, we were able to exclude common factors that play a role in drug pharmacokinetics as 
being responsible for the lower tafamidis concentrations seen preferentially in nonresponders; however, it 
is worth noting that our analysis did not fully exclude the hypothesis of  faster tafamidis excretion or poor 
absorption in patients with low tafamidis levels.
A predictive model of  response to tafamidis. The observations in the preceding sections show that several 
variables that can be measured before or soon after tafamidis therapy is initiated vary significantly among 
Figure 2. Concentration of tetrameric plasma 
TTR at baseline is significantly different 
between responders and nonresponders. (A) 
Concentration of tetrameric plasma TTR (CTTR) 
at baseline is significantly higher in responders 
than in nonresponders; P values were calculated 
using Kruskal-Wallis test with Dunn’s multi-
ple-comparisons correction; nNR = 55, nPR = 72, 
nR = 70. (B) No differences were seen between 
men and women in CTTR at baseline. P values 
were calculated with Mann-Whitney U test; 
nmen = 106, nwomen = 91; for A and B, horizontal 
bars represent median and error bars represent 
interquartile range. (C) Weak correlation or no 
correlation is seen between CTTR and SNF (n = 
194), and (D) CTTR and NIS at baseline (n = 197); 
for C and D, r represents Spearman’s correlation 
coefficient. Red line represents best fit; curved 
red lines represent 95% confidence intervals of 
the best fit.
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Figure 3. Concentration of tafamidis in plasma and extent of tetramer stabilization are different according to response classification. (A) Diagram 
representing the TTR amyloidogenesis cascade hypothesis and the experimental approach for this experiment. Using samples collected at baseline (bas) 
and after 12 months of therapy, the rate of dissociation of the TTR tetramer was determined at baseline and after 12 months of tafamidis therapy; the 
extent (Δln kex) of TTR tetramer stabilization was calculated as shown in the figure; additionally, total concentration of tafamidis (CTaf) in plasma was 
measured in the 12-months samples. (B) Total CTaf in plasma is significantly lower in nonresponders (n = 62) when compared with partial responders (n = 
75) and responders (n = 71). (C) Total CTaf in women is not significantly different according to response classification (NR: n = 17, PR: n = 26, R: n = 49). (D) 
CTaf in men is significantly lower in nonresponders (NR: n = 45, PR: n = 49, R: n = 22). (E) Correlation between plasma CTaf and the extent of TTR stabilization 
(n = 194), showing that a higher CTaf is positively correlated with a more stable TTR tetramer. r, Spearman’s correlation coefficient; red line represents best 
fit (R2 = 0.26); curved red lines represent 95% confidence intervals of the best fit. (F) TTR in plasma of male nonresponders (n = 40) is significantly less 
stable when compared with male partial responders (n = 44) and male responders (n = 22); for B–D and F, horizontal bars represent median and errors bar 
represent interquartile range. P values were calculated using Kruskal-Wallis test with Dunn’s multiple-comparisons correction.
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nonresponders, partial responders, and responders. Therefore, these variables could in principle be used to 
predict a patient’s responsiveness to tafamidis. To explore this possibility, we converted the categorical out-
come variable (i.e., the response classification), which has the values “nonresponder”, “partial responder”, 
and “responder”, to a numerical variable with corresponding values of  0, 0.5, and 1, respectively. We then 
fit the linear model shown below to the numericized responses for the 210 patients in our database:
SR = a0 + bNF×SNF + bM×M + bM-Taf×M×CTaf + bTTR×CTTR,   (Equation 2)
where SR is the numericized response score; a0 is the constant of  regression; SNF is the neurophysiology score 
(a sum of several SNAPs and CMAPs); M is the sex of  the patient, coded as 1 for males and 0 for females; 
and CTaf and CTTR are the micromolar plasma concentrations of  tafamidis and tetrameric TTR, respectively.
Note that the fourth term has a product of  2 variables, M and CTaf. Given the coding for M, M×CTaf = 
0 for females and M×CTaf = CTaf for males. This interaction variable therefore accounts for our observation 
that plasma CTaf differed significantly among the response classifications only for male patients.
The quantities denoted by b with subscripts are the regression coefficients for the corresponding vari-
ables. The best-fit values for the parameters are as follows: a0 = 0.195 ± 0.076, bNF = 0.0046 ± 0.0007, bM = 
−0.447 ± 0.083, bM-Taf = 0.027 ± 0.008 μM
−1, and bTTR = 0.068 ± 0.022 μM
−1. The model captures a moder-
ate amount — about 35% (R2 = 0.35) — of  the variation in the responses of  individual patients to tafamidis 
therapy. However, given the discrete nature of  the response classification variable, this is not the best way 
to judge the utility of  the model. Instead, we divided the model outputs into quintiles and calculated the 
proportions of  nonresponders, partial responders, and responders in each quintile (Figure 5A).
Figure 4. Variation in CTaf is not explained by sex or by tafamidis glucuronidation. (A) CTaf is not different between 
women and men at 12 months (P = 0.70; nmen = 116, nwomen = 92) and (B) 24 months of therapy (P = 0.77; nmen = 116, nwomen 
= 93); for A and B, horizontal bars represent median and errors bar represent interquartile range. P values were calculat-
ed using a Mann-Whitney U test. (C) Left panel: Chromatogram representing fluorescence detection of tafamidis-gluc. 
and unmetabolized tafamidis in the plasma of a patient taking oral tafamidis (for details, see Supplemental Methods 
and Supplemental Figure 8). Right panel: Correlation between the AUC for the tafamidis peak and the metabolite peak 
(tafamidis-gluc.). r, Spearman’s correlation coefficient; red line represents best fit (R2 = 0.44); curved red lines repre-
sent 95% confidence intervals of the best fit.
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The proportions of  each response category in a given quintile can then be taken as estimates of  the 
probabilities that a new patient who also falls into that quintile (based on their calculated SR, obtained from 
evaluating Equation 2 with that patient’s sex, SNF, CTaf, and CTTR values) will have a given response to tafa-
midis. For example, a hypothetical male patient (M = 1) with SNF = 32.9, CTaf = 14.9 μM, and CTTR = 3.6 μM 
has a calculated response score value of  SR = 0.195 + (0.0046 × 32.9) + (−0.447 × 1) + 0.027 × 1 × 14.9 + 
0.071 ± 0.068 × 3.6 = 0.55. An SR of  0.55 would place this hypothetical patient in the third quintile (Figure 
5A), where their probability of  being a nonresponder, partial responder, or responder is 19% ± 6%, 43% ± 
8%, or 38% ± 7%, respectively (uncertainties represent the standard errors for proportions).
The robustness of this model is difficult to assess using traditional methodology employed to evaluate bina-
ry classifier systems (for example, receiver operating characteristic [ROC] curves) because it has 3, rather than 2, 
classifications. Therefore, to give a sense of the ability of our model to discriminate between the response catego-
ries, we show 2 ROC curves for our model (Figure 5B): one showing discrimination between the combined non-
responder and partial responder categories versus the responder category (NR+PR vs. R; purple curve) and the 
other discrimination between the nonresponder category versus the combined partial responder and responder 
categories (NR vs. PR+R; cyan curve). The former curve emphasizes identification of responders, whereas the 
latter emphasizes identification of nonresponders. The AUCs of the 2 ROC curves were 0.82 and 0.81, respec-
tively, indicating that our model is effective at discriminating both responders and nonresponders.
The relative importance of  the variables in our model can be assessed by leaving each one out of  the 
model in turn and assessing the performance of  the abbreviated models. This exercise revealed that SNF was 
the most important variable in our model, since leaving it out diminished the AUCs of  the ROC curves to 
0.75 for the NR+PR vs. R curve and 0.72 for the NR vs. PR+R curve. The importance of  the other vari-
ables decreased in the following order: sex (M) > M×CTaf > CTTR. The best fit parameters and AUCs for the 
abbreviated models are presented in Supplemental Table 3.
NIS was left out of  our model because SNF and NIS provide somewhat redundant information about 
the extent of  disease progression in terms of  nerve function, but SNF better discriminated responders, partial 
responders, and nonresponders (Table 2). In fact, SNF decreased exponentially as NIS increased, so that SNF 
decreased precipitously over a narrow range of  small NIS values (Supplemental Figure 9). Thus, SNF seems to 
be more sensitive than NIS to early disease progression in FAP. However, NIS is more widely available and 
a fully validated clinical score. For this reason, we built an alternative model (Model-NIS), in which SNF was 
replaced by NIS (Supplemental Figure 10). Finally, since the biochemical methods to measure CTaf and CTTR 
might not be available in all clinical centers following these patients, we built a simplified version of  our model 
(Model-S), in which plasma measurements of  tafamidis and TTR concentrations were left out (Supplemental 
Figure 11). In both cases (Model-NIS and Model-S), discrimination between the 3 response groups was still 
possible (Supplemental Figures 10 and 11), although not as clear as with the original model (Figure 5A).
The usefulness of  our model for estimating an individual patient’s chances of  being a nonresponder, 
partial responder, or responder to tafamidis therapy (20 mg qd) can only truly be tested by prospectively 
applying it to a cohort of  patients as they begin treatment and then comparing the proportions of  each 
response category in each quintile to the expected proportions from our model. However, in the interim, 
Table 3. Relation between plasma CTaf and patient characteristics that could influence tafamidis pharmacokinetics
CTaf (at 12 mo) CTaf (at 24 mo)
r P value r P value
Age –0.0485 0.4868 –0.0721 0.2993
Weight –0.0129 0.8528 –0.0878 0.2127
BMI –0.0013 0.9846 –0.0818 0.2460
mBMI 0.1067 0.1260 0.0208 0.7687
eGFR –0.0482 0.4903 –0.0065 0.9261
AST –0.0403 0.5634 –0.0606 0.3847
ALT –0.1029 0.1390 –0.1690 0.0147
BMI is shown in kg/m2; mBMI (modified BMI) in kg/m2 × g/L of serum albumin; and eGFR in mL/min/1.73 m2. AST, aspartate transaminase; ALT, alanine 
transaminase; eGFR, estimated glomerular filtration rate. Only ALT at 24 months is not independent from CTaf (P < 0.05 highlighted in bold); however, the 
Spearman’s correlation coefficient (r) for ALT suggests negligible correlation.
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.126526
C L I N I C A L  M E D I C I N E
we were able to test the validity of  our approach by randomly dividing the patient data set into “training” 
and “test” sets. The training set was used for fitting the model, setting the boundaries for the quintiles, and 
calculating the expected proportions of  each response category in each quintile. The fitted model was used 
to calculate response values for the test set, which were then sorted into the quintiles defined by the training 
group, and the proportion of  each response category in the quintiles from the test set was compared with 
the expected proportions from the training set. We repeated this procedure 100 times and found that the 
proportions of  the responder categories in the quintiles from the training set predicted the proportions in 
the test set with a root mean square deviation of  ±14%. This error was consistent with the standard errors 
shown in Figure 5 for the proportions in the quintiles calculated from the full data set — which are typically 
on the order of  7%–8% — given that the training and test sets were each half  the size of  the full data set. 
These results suggest that our model can indeed be useful for predicting the likelihood that a given patient 
will respond to tafamidis therapy.
Discussion
Herein, we have shown that over a maximum follow-up period of  66 months, at least one-third of  
patients taking tafamidis respond to the drug with almost complete cessation of  disease progression. Our 
criteria to define responders (resulting in a median NIS score change from baseline ≤0 for 54 months) 
are more stringent than the criteria used in previous studies (change in NIS in the lower limbs [NIS-LL] 
<2 points in 18 months) (8, 13). We identified an additional one-third of  patients with partial remission 
of  important disease manifestations while continuing progressing from other disease aspects (defined 
as partial responders). The lack of  an untreated control group was a limitation of  our study that could 
Figure 5. Predictive model 
of response to tafamidis. 
(A) The response score (SR) 
interval of each quintile is 
shown in the x axis, and the 
probability for each response 
classification within each 
quintile is shown in the y 
axis. Error bars represent 
95% confidence limits. (B) 
Receiver operating character-
istic (ROC) curves for the pre-
dictive model. Purple curve: 
Discrimination between the 
combined nonresponder and 
partial responder categories 
versus the responder catego-
ry (NR+PR vs. R). True posi-
tives in this case are patients 
who are nonresponders or 
partial responders with SR 
below a given cutoff; false 
positives are responders with 
SR below a given cutoff (SR 
cutoffs are shown as purple 
numbers). Cyan curve: Dis-
crimination between the non-
responder category vs. the 
combined partial responder 
and responder categories (NR 
vs. PR+R). True positives in 
this case are patients who are 
nonresponders with SR below 
a given cutoff; false positives 
are partial responders or 
responders with SR below a 
given cutoff (SR cutoffs are 
shown as cyan numbers).
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not be avoided, given that tafamidis is the standard of  care for patients in Portugal. However, one can 
compare our results with previously reported natural history studies or placebo-controlled clinical trials 
for FAP. It is clear that patients in the responder and partial responder groups progressed slower (median 
NIS progression rate: 0 points/yr for responders and 1.8 points/yr for partial responders) than what was 
described in the pivotal tafamidis study (8, 13) for the placebo-treated cohort (NIS-LL progression rate 
of  approximately 5 points in 12 months), which includes a patient population comparable to ours. Addi-
tionally, a combined analysis of  252 matched untreated FAP patients had an NIS-LL progression rate 
of  2.8 points/yr (17). A multinational natural history study including more advanced patients (median 
baseline NIS of  32) estimated a rate of  NIS progression of  14.3 points/yr (29). These data confirm that 
untreated patients progress at a rate of  more than 2 points per year in their NIS-LL. The fact that NIS-LL 
is a subpart of  NIS will lead to an identical or higher progression rate when considering the total score as 
we do in the current study. Additionally, we report a third of  patients using our more stringent analysis as 
nonresponders with a median NIS progression rate of  5.9 points/yr, which is within the range reported 
for the rate of  progression of  untreated FAP patients in the above-mentioned placebo-controlled studies 
or observational and natural history studies (8, 13). Moreover, our data support the tafamidis registration 
trial (8), in which 60% of  the efficacy-evaluable population was considered to be “NIS-LL responders.” 
The response classification by one single expert is a weakness in our study; however, the clinical scores 
and the opinions of  the neurologists observing each patient were taken into consideration by the expert. 
A consensus of  multiple experts on response classification should be the aim of  future studies. It is 
important to note that progression of  Norfolk QOL-DN scores was not a useful measure of  tafamidis 
response in this group of  patients. Patients who were unequivocally progressing from their motor and 
sensory neuropathy showed minimal changes in this patient-reported outcome measure, possibly reflect-
ing patients’ expectations of  a treatment effect and the open-label nature of  this study.
One limitation of  our 3-group approach is that, while clinically rigorous and supported by different 
scores, it might have led us to lose power in our prediction model. Despite this limitation, we believe that 
this classification-by-response model can be used to rigorously compare mechanistically distinct therapies 
in the commercial setting, where observation times are longer and more meaningful. Additionally, the 
3-group approach can be used to evaluate patients with other FAP genotypes treated with tafamidis at the 
same or higher doses. Ideally, data from multiple clinical centers should be combined in order to acquire 
information on larger patient data sets.
An important aim of this study was to identify baseline demographic and clinical characteristics and 
identify plasma biomarkers that can be used as tafamidis outcome (or response-to-therapy) predictors. Our 
data show that female sex is a clear predictor of  a positive response to tafamidis. These data raise the possi-
bility that sex differences influence underlying disease mechanisms, a hypothesis that is also supported by the 
peripheral blood cell transcriptional profiling differences between men and women reported previously (30). 
Future studies of  disease-specific and response-to-therapy biomarkers should take sex in consideration. Our 
data also confirm that early-stage patients are more likely to respond positively to tafamidis. This raises the 
hypothesis that TTR dissociation, misfolding, and aggregation initiate a downstream cascade of  abnormal 
events that can auto-perpetuate itself  even when the proteinopathy trigger to pathology is removed by tafa-
midis treatment. A better understanding of  early and late disease events, as well as the role of  neuroinflam-
mation, is essential, as it may lead to complementary treatment approaches. Additionally, we have identified 
tafamidis concentration (and consequently TTR kinetic stabilization) as a predictor of  response in a subset of  
patients, predominantly men. This finding raises the possibility that some FAP patients might benefit from a 
higher dose of  tafamidis, and this should be further investigated.
These data also highlight the need for early diagnostic biomarkers in FAP to allow early initiation of  
therapy. Using a method that detects only natively folded tetrameric TTR, we found that patients who 
had higher levels of  native TTR at baseline were more likely to become responders than nonresponders. 
Future studies should further investigate the differences between our A2-UPLC tetrameric TTR quan-
tification method and the routinely used immunoturbidimetric methods to define TTR levels as a prog-
nostic indicator of  response to kinetic stabilizers. The reasons why FAP patients have low levels of  TTR 
are not understood. Interestingly, reduced CSF levels of  Aβ42 were established as diagnostic biomarkers 
after longitudinal studies following genetic Alzheimer’s disease cases (31). Analogously, longitudinal 
follow-up of  presymptomatic FAP mutation carriers should help define the role of  native TTR levels in 
detecting early symptomatic disease stages.
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Using data from this retrospective patient study, we were able to build a predictive model of  response 
to tafamidis (20 mg qd), which can potentially be used in the clinical setting to help clinicians and patients 
predict response, and eventually to prioritize therapy. To build the model, we used plasma tafamidis con-
centration at 12 months (CTaf); however, based on the reported pharmacokinetic characteristics of  tafa-
midis and also on our comparisons between 12 and 24 months, we consider that concentration after 1 
month of  therapy should be used in future studies to further validate this model. Moreover, additional 
response-to-therapy biomarkers that might strengthen this model are currently under investigation using 
unbiased plasma proteomic approaches. It is important to keep in mind that our model was built using 
patients with a predominantly neuropathic phenotype, and most of  our patients were heterozygous for the 
common Val30Met mutation (98.1%). Future studies with other mutations and mixed cardiac/neuropathy 
phenotypes should indicate whether a similar model can be applied more broadly.
Finally, our work comprises detailed clinical and biochemical human data supporting the amyloid 
hypothesis applied to the TTR amyloidoses. The amyloid hypothesis posits that the misfolding and aggre-
gation of  a given protein into a spectrum of  non-native structures, including cross-β-sheet amyloid fibrils, 
is linked to tissue degeneration (32). Overall, disease progression is slowed when the dissociation rate of  
plasma TTR tetramers is reduced by correspondingly higher plasma concentration of  the kinetic stabilizer 
tafamidis. This provides a direct link between neuropathy progression and the inhibition of  TTR aggrega-
tion via TTR native tetramer stabilization.
Methods
Study design
This was a nonrandomized, longitudinal observational study of  all patients eligible to start therapy with 
tafamidis in a single clinical center (Unidade Corino de Andrade), with at least 24 months follow-up from 
baseline (or a minimum of  18 months for patients who did not respond during that period of  time), up to 
66 months. Patients were considered eligible to start therapy with tafamidis when they met the following 
criteria: (i) confirmed TTR genetic mutation, (ii) tissue biopsy with confirmed Congo red–positive amyloid 
deposition, and (iii) symptoms or signs confirming involvement of  the peripheral nervous system (sensory, 
autonomic, and/or motor). For this study, the following exclusion criteria were considered: (i) patients 
included in the clinical trial Fx005 (ClinicalTrials.gov, NCT00409175) or Fx006 (NCT00791492), (ii) inclu-
sion in the open-label add-on trial with the siRNA drug patisiran (NCT01961921), (iii) comorbidities with 
peripheral and/or central nervous system clinical manifestations, (iv) therapy suspension before 2 years for 
reasons other than nonresponse, (v) absent clinical follow-up after 12 months of  therapy, (vi) no baseline or 
subsequent plasma samples collected, and (vii) refusal to participate in the study.
Study population
All patients eligible for this study with baseline assessment between July 2012 and January 2016 were 
included. Patients were assessed at treatment start (baseline visit) and subsequently every 6 months up to 
5.5 years. Patients were observed by one of  6 trained neurologists working or previously working at the 
FAP clinic. When considered necessary, they were also observed by a cardiologist, ophthalmologist, and/
or nephrologist. A standardized protocol included the outcome measures detailed below: NIS, Norfolk 
QOL-DN, weight, routine neurophysiologic tests including sensory and motor nerve amplitude measure-
ments, and routine blood tests. Information regarding TTR mutation was available for all patients. Disease 
duration was based on judgment by the treating neurologist regarding the information provided by each 
patient for the onset of  symptoms and signs associated with TTR-FAP.
Outcome measures
NIS, Norfolk QOL-DN, weight, BMI, and mBMI. Patients had their NIS score determined at baseline and 
every 6 months. For most patients, the neurologist scoring was the same at baseline and follow-up, reducing 
the chance for interobserver variability. Concomitantly, patients had height measurement at baseline or at 
an asymptomatic stage and weight measurements at all visits of  the study. Serum albumin was determined 
as part of  the routine blood testing at the hospital clinical laboratory.
SNF. Routine nerve conduction studies were performed concurrently with each neurology observation. 
The SNAPs of  ulnar and sural nerves were measured (peak to peak). Average SNAP was used when bilat-
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eral measurements were available for the same nerve. Most patients had bilateral sural nerve and unilateral 
ulnar nerve SNAP measurements. CMAPs of  the tibial, peroneal, and ulnar nerves were also determined, 
in most cases unilaterally. In patients for whom bilateral measurements were available, average CMAPs 
were calculated. The neurophysiology score corresponds to: sural SNAP + ulnar SNAP + tibial CMAP + 
peroneal CMAP + ulnar CMAP. No adjustments for age, sex, or height were made. In cases where sensory 
or motor potentials were not present in a specific nerve, repeated measurements were not attempted in the 
same nerve in the subsequent visit, and the corresponding SNAP or CMAP was considered 0.
Routine blood tests
Routine blood tests were performed on all patients at the hospital clinical laboratory, including renal func-
tion (creatinine, blood urea nitrogen [BUN], and uric acid), liver function (total bilirubin, aspartate and ala-
nine transaminases, alkaline phosphatase, gamma-glutamyl transaminase, serum albumin), cardiac markers 
(troponin T [Roche Elecsys high-sensitivity], NT-Pro-BNP [Roche Elecsys]), total cholesterol, triglycerides, 
serum albumin, total protein, free thyroxine, thyroid-stimulating hormone, complete blood count, sedimen-
tation rate, and C-reactive protein. Urine samples were assessed for albuminuria and proteinuria. eGFR was 
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (33).
Responder classification
In January 2018, i.e., 66 months after the study began, an expert in TTR-FAP (TC) classified all patients as 
responders, partial responders, and nonresponders. Patient clinical records were scrutinized individually. 
Additionally, NIS, Norfolk QOL-DN, weight, and neurophysiology score were also considered. Respond-
ers were patients who showed no progression of  sensory, autonomic, and/or motor neuropathic symptoms 
and signs. The usual criterion of  progression of  less than 2 points in the NIS score was not applied (29). 
Patients were classified as nonresponders when they showed a continuous and rapid worsening of  senso-
ry, motor, and/or autonomic neuropathy not different from the expected progression without therapy. A 
group of  partial responders included patients who showed slower than expected progression of  sensory 
and/or motor neuropathy with stability of  autonomic nervous system manifestations, or patients who con-
tinued progressing from sensory and/or motor neuropathy while showing a manifest improvement of  the 
autonomic neuropathy and weight gain. Autonomic nervous system manifestations can be devastating in 
these diseases; therefore, we decided that improvement of  objective symptoms such as diarrhea, orthostatic 
hypotension and erectile dysfunction, even in the presence of  continuous progression of  sensory neuropa-
thy, should be considered at least as a partial response. None of  the biochemical measurements regarding 
TTR concentration, tafamidis concentration, or TTR stabilization played any role in the classification of  
patients as responders, partial responders, or nonresponders.
Plasma samples
Blood was collected in tubes with EDTA, followed by centrifugation at 1500 g for 20 minutes. The resulting 
supernatant (plasma) was carefully removed and centrifuged for an additional 20 minutes to remove any 
remaining cells. Plasma was transferred to 1.5 mL cryovials with a cap and stored at −75°C until it was 
shipped. After shipment in dry ice, frozen patient plasma samples were kept at −80°C. All plasma samples 
were thawed at ambient temperature before being aliquoted and used for the different assays. No more than 
2 cycles of  freeze-thaw were applied. Most patients had blood collection at baseline and every 6 months. 
For most assays, only baseline and annual samples were analyzed (12, 24, 36, 48, and 60 months). In the 
cases where a 12-month sample was not available, a 6-months or 18-month sample was used; similarly, 
when a 24-month sample was not available, an 18-month sample was used. Blood from healthy volunteers 
was obtained from the Scripps Research Institute Normal Blood Donor Services Center.
Recombinant protein expression and purification
Recombinant WT TTR (WT-TTR) and dual-FLAG-tagged WT-TTR (FT2-WT-TTR) were expressed and 
purified from Escherichia coli as described previously. The molar absorptivity (ε) of  WT-TTR (73,800 M−1 
cm−1) and FT2-WT-TTR (85,720 M
−1 cm−1) tetramers in standard phosphate buffer was used to prepare 
TTR solutions of  known concentration. After purification, aliquots were stored at –80°C in 50 mM phos-
phate buffer pH 7.6 (standard phosphate buffer).
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Measurement of tetrameric TTR in plasma
Tetrameric TTR levels in plasma were quantified using a Waters ACQUITY H-Class Bio-UPLC instrument 
employing a Waters Protein-Pak Hi Res Q ion exchange column (strong anion exchanger, 5-μm particle 
size, 4.6 × 100 mm column). A standard curve was prepared using recombinant WT-TTR at concentrations 
of  10 μM, 5 μM, and 2.5 μM in 50 mM phosphate buffer, pH 7.6. Subjects’ samples and 2 healthy control 
samples were thawed and filtered using a 0.45-μm syringe filter. Subjects’ plasma samples, healthy control 
plasma, and standard curve samples were aliquoted (9 μL) in duplicate into a 96-well plate with 1 μL of  the 
fluorescent small molecule A2 (500 μM) in each well (34). The same 2 healthy controls from the Normal 
Blood Donor Services Center were used in duplicate in each plate to determine intra-assay variability. After 
incubation, the samples were injected into the ion exchange column and separated using a linear 24%–29% 
buffer B gradient over 10 minutes (flow 0.5 mL/min, buffer A: 25 mM Tris pH 8; buffer B: same as buffer 
A, but with 1 M NaCl added). The TTR-(A2)2 fluorescent conjugate peak (excitation 328 nm, emission 
430 nm; elution time, 6 minutes) was integrated, and the concentration of  TTR in patient samples was 
quantified using the standard curve. Intraplate variability was ≤15%, and interplate variability was ≤10%.
Subunit exchange assay to assess kinetic stability
Subunit exchange rates were determined as described previously (25) with the following minor modifica-
tions. FT2-WT-TTR (2 μL of  a 40-μM solution) was added to plasma (40 μL) to afford a final FT2-WT-TTR 
concentration of  2 μM. The samples were incubated at 25°C for 48 hours to allow subunit exchange to 
occur. At 48 hours, the reaction was stopped by the addition of  the fluorogenic small molecule A2 at a final 
concentration of  500 μM. The samples were incubated with A2 for at least 3 hours to allow complete cova-
lent labeling of  TTR, before being injected into the ion exchange column and separated using a linear 24%–
39% buffer B gradient over 29 minutes using the same buffers as described above. The rate of  exchange for 
all subunit exchange experiments was calculated using peak 1, as previously described. All patient samples 
were analyzed in duplicate (technical replicates), and most samples corresponding to the same patient were 
run in the same plate. Coefficient of  variability within the samples was ≤15%. The same 2 healthy control 
plasmas were used in duplicate in all subunit exchange plates. The inter-plate variability was ≤17%.
HPLC analysis of tafamidis concentration
Tafamidis levels were quantified in the plasma samples employing the HPLC method previously described 
(26), with the following minor modifications. Four sets of  standard curves were generated simultaneously by 
adding tafamidis (using a 50× stock solution in DMSO) to a healthy donor plasma and incubating overnight 
at 37°C. The final CTaf employed for the standard curve equaled 0, 1, 3, 6, or 12 μM. Protein extraction was 
performed by mixing 40 μL of each standard curve/healthy plasma sample with 200 μL acetonitrile contain-
ing 1% (w/v) trichloroacetic acid. Samples were shaken at 1500 rpm for 30 minutes at 25°C and then centri-
fuged for 10 minutes at maximal speed in a tabletop microcentrifuge. The supernatant was separated into 4 
tubes (50 μL each), and each tube was kept at –80°C before use. One experiment was done to confirm that 
frozen standard curve tubes and freshly prepared standard curve samples gave exactly the same results. Each 
day, 10–15 aliquots from patients taking tafamidis were thawed. 20 μL plasma was mixed with 100 μL aceto-
nitrile containing 1% (w/v) trichloroacetic acid. Shaking and centrifugation were done as with the standard 
curve samples. After protein extraction, standard curve and patient sample supernatants (10 μL) were injected 
into a Thermo Fisher Scientific BetaBasic 18 (50 × 4.6 mm) column using an Agilent 1260 Infinity HPLC 
with fluorescence detection (excitation at 310 nm, emission at 370 nm). A gradient from 90% A (water 95%, 
4.9% acetonitrile, 0.1% trifluoroacetic acid)/10% B (acetonitrile 95%, 4.9% water, 0.1% trifluoroacetic acid) 
to 0% A/100% B was run for 20 minutes at 1 mL/min. A peak at ~13 mL was seen both in plasma samples 
with tafamidis added ex vivo and in patient plasma samples. Pure tafamidis in DMSO also produces a peak 
at the same retention time, and we have previously shown by mass spectrometry that this peak corresponds 
to tafamidis in patient samples. Under the conditions used, the detection limit for tafamidis was 6.3 nM. All 
samples (including patient and standard curves) were prepared and injected in duplicate. The coefficient of  
variability was ≤10%. To confirm that no tafamidis was lost in the protein precipitate using our acetonitrile 
method, we performed one experiment in which tafamidis was added ex vivo to healthy control plasma (5, 
10, 15 μM), protein was extracted as detailed above, and concentration was measured using the same HPLC 
method and standard curve of  pure tafamidis in DMSO. Calculated concentrations were 5.34 ± 0.05 μM, 
11.15 ± 0.07 μM, and 15.21 ± 0.07 μM, showing that our method measures total CTaf in plasma.
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.126526
C L I N I C A L  M E D I C I N E
Tafamidis-gluc. was synthesized as described in Supplemental Figure 8 and Supplemental Methods. 
Fluorescence absorption and emission scans were taken to confirm that tafamidis-gluc. has the same fluo-
rescence properties as unmodified tafamidis (i.e., maximum excitation 310 nm and maximum emission 370 
nm). Tafamidis-gluc. was then injected in the HPLC using the same method as above, producing a unique 
peak at ~9 mL. We noticed that in our analysis of  patient samples, the same peak at 9 mL was seen, and 
that this peak was not present when tafamidis was added ex vivo to healthy plasma. We performed the 
same experiment as above to confirm that all tafamidis-gluc. was extracted using our acetonitrile method. 
We then retrospectively analyzed 146 chromatograms and compared the AUC of  the tafamidis peak (13 
mL) to the tafamidis-gluc. peak (9 mL). While doing these experiments, we noticed that synthesized taf-
amidis-gluc. was hydrolyzed in healthy plasma when incubated overnight at 37°C. Therefore, we cannot 
exclude that some endogenous tafamidis-gluc. was being hydrolyzed to tafamidis, leading to an overestima-
tion of  plasma tafamidis levels.
Prediction model
The linear model represented by Equation 2 was fit to the numericized Response values using linear regres-
sion as implemented in Mathematica 11.3 (Wolfram) or Excel (Microsoft). In the few cases where data were 
missing (3 of  210 SNF scores; 9 of  210 TTR concentrations; and 2 of  210 tafamidis concentrations), we used 
mean imputation to replace them; that is, the missing values were replaced with the average value for patients 
of  the same sex and response category. The patients were then divided into quintiles based on their calculated 
response values and the proportions of  each response category in each quintile were calculated. The standard 
errors of  the proportions were calculated as usual for probabilities, i.e., standard error = (Pi × (1 − Pi)/n)
1/2, 
where Pi is the probability of  event i and n is the number of  patients in the sample (for our quintiles, n = 210/5 
= 42) (35). Note that this standard error only considers the probabilities of  the proportions individually. The 
confidence intervals of  the proportions considered jointly are larger by about 60% (35). The alternative mod-
els, Model-NIS and Model-S, were created in an exactly analogous way.
The validation of  the model by comparing the results from a training subset of  the patient database 
with a test subset was also performed using Mathematica 11.3 to randomly split the patients into groups of  
equal size, fit the data to the training set as described above, split the patients into quintiles, and calculate 
the proportions of  nonresponders, partial responders, and responders in each quintile. The fitted model 
was then applied to the test data set; the patients in the test dataset were sorted into the quintiles obtained 
from the training dataset; and the proportions of  nonresponders, partial responders, and responders in each 
quintile were calculated. This process was iterated 100 times, and then the proportions of  each response 
category were compared in the training and test datasets for each iteration. Finally, the root mean square 
of  the differences was calculated.
Blinding
All plasma samples were analyzed for CTaf, tetrameric TTR concentration, and TTR kinetic stability by a 
researcher blinded to response to therapy classification. Treatment status was not blinded. All patients were clas-
sified as responders, partial responders, or nonresponders by a researcher blinded to the biochemical analysis.
Statistics
All graphs and statistics were prepared in Prism 7 (GraphPad Software). For comparisons among 3 or more 
groups, we used a Kruskal-Wallis test with Dunn’s multiple comparison correction. For comparisons between 
only 2 groups, we used a 2-tailed Mann-Whitney U test. Correlations were assessed by calculating the Spear-
man’s correlation coefficient. All P values are indicated in the legends and figures. Scatter plots include a 
horizontal bar for the median value and error bars that represent the first quartile (Q1) and the third quartile 
(Q3). For analyses in which variables were compared among response categories at baseline, missing values 
were few (in the worst case, there were 13 missing values of  210 for baseline subunit exchange rate constants) 
and occurred at random because of  technical problems (insufficient sample for the assay, high sample vis-
cosity, etc.). Moreover, these missing values were spread across the response categories (5 nonresponders, 6 
partial responders, and 2 responders). Therefore, these values were simply omitted from the analysis. For our 
longitudinal analysis of  the change in NIS and weight as a function of  time, we had many more data points 
at early than later time points. This circumstance arose simply because the patients in our population started 
tafamidis treatment on a rolling basis between July 2012 and January 2016. Data for the later time points were 
1 6insight.jci.org   https://doi.org/10.1172/jci.insight.126526
C L I N I C A L  M E D I C I N E
only available for patients who began tafamidis therapy at the beginning of  our window. This observation 
suggested that the missing values were missing at random and could be omitted.
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